Novo lead in obesity race starts to sag – Reuters – DC Initiative on Racial Equity
Skip to content Skip to footer

Flags are seen outside the Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen

Register now for FREE unlimited access to

LONDON, Dec 20 (Reuters Breakingviews) – Novo Nordisk (NOVOb.CO) shares lost some 11% of their value after the group said sales of its new obesity drug would be hurt by problems at a supplier. The treatment, called Wegovy, is a leading contender in the potentially vast market for weight-loss drugs, which Citigroup estimates could top $10 billion in annual sal

Read Full Article at

Leave a comment

DC Initiative on Racial Equity

© 2022. All Rights Reserved.